Nabota

Nabota Use In Pregnancy & Lactation

Manufacturer:

Daewoong Pharma

Distributor:

Daewoong Pharma
Full Prescribing Info
Use In Pregnancy & Lactation
There are no adequate and well-controlled studies in pregnant women.
When pregnant mice and rats were injected intramuscularly during the period of organogenesis, the developmental NOEL (No Observed Effect Level) of other botulinum toxin was 4 U/kg. Higher doses (8 or 16 U/kg) were associated with reductions in fetal body weights and/or were decreased fetal skeletal ossification. In a range finding study in rabbits, daily injection of 0.125 U/kg/day (days 6 to 18 of gestation) and 2 U/kg/day (days 6 to 13 of gestation) produced severe maternal toxicity, abortions and/or fetal malformations. Higher doses resulted in death of the dams. The rabbit appears to be a very sensitive species to this drug. The patient should be apprised of the potential risks, including abortion or fetal malformations which have been observed in rabbits.
It is not known whether botulinum toxin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.
Administration of this product is not recommended during pregnancy or lactation.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in